The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities
Paolo Angelo Cortesi(University of Milano-Bicocca), Mario Strazzabosco(Smilow Cancer Hospital), Christophe Duvoux(Université Paris-Est Créteil), LG Mantovani(IRCCS Istituto Auxologico Italiano), Giovanni Perricone(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), L Belli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Chiara Mazzarelli, Stella De Nicola(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), G Cesana(University of Milano-Bicocca), Rita Facchetti(Laiko General Hospital of Athens)
Cited by 31
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General Population
|Circulation|2005|1k
Long-Term Risk of Mortality Associated With Selective and Combined Elevation in Office, Home, and Ambulatory Blood Pressure
|Hypertension|2006|693
Global Burden of Multiple Myeloma
|JAMA Oncology|2018|631
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma
|Transplantation|2015|417